Retraction Note to: A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.
作者信息
Zhang Wenda, Yu Wenying, Cai Guiping, Zhu Jiawen, Zhang Chao, Li Shanshan, Guo Jianpeng, Yin Guoping, Chen Chen, Kong Lingyi
机构信息
State Key Laboratory of Natural Medicines, Department of Natural Medicinal Chemistry, China Pharmaceutical University, 24 Tong Jia Xiang, 210009, Nanjing, China.
出版信息
Cell Death Dis. 2021 May 21;12(6):522. doi: 10.1038/s41419-021-03809-2.
Abstract
摘要
相似文献
1
Retraction Note to: A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.撤回说明：隐丹参酮KYZ3的一种新型合成衍生物作为三阴性乳腺癌治疗的STAT3抑制剂。
Cell Death Dis. 2021 May 21;12(6):522. doi: 10.1038/s41419-021-03809-2.
2
A new synthetic derivative of cryptotanshinone KYZ3 as STAT3 inhibitor for triple-negative breast cancer therapy.一种新型丹参酮 KYZ3 合成衍生物作为 STAT3 抑制剂用于三阴性乳腺癌治疗。
Cell Death Dis. 2018 Oct 27;9(11):1098. doi: 10.1038/s41419-018-1139-z.
3
Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells.隐丹参酮通过阻断DU145前列腺癌细胞中的二聚化来抑制组成型信号转导子和转录激活子3的功能。
Cancer Res. 2009 Jan 1;69(1):193-202. doi: 10.1158/0008-5472.CAN-08-2575.
4
LLY17, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer.LLY17，一种新型小分子 STAT3 抑制剂，可诱导三阴性乳腺癌细胞凋亡，抑制细胞迁移和肿瘤生长。
Breast Cancer Res Treat. 2020 May;181(1):31-41. doi: 10.1007/s10549-020-05613-6. Epub 2020 Apr 2.
5
A novel small molecule STAT3 inhibitor SLSI-1216 suppresses proliferation and tumor growth of triple-negative breast cancer cells through apoptotic induction.一种新型小分子 STAT3 抑制剂 SLSI-1216 通过诱导细胞凋亡抑制三阴性乳腺癌细胞的增殖和肿瘤生长。
Biochem Pharmacol. 2020 Aug;178:114053. doi: 10.1016/j.bcp.2020.114053. Epub 2020 May 23.
6
Cryptotanshinone suppresses key onco-proliferative and drug-resistant pathways of chronic myeloid leukemia by targeting STAT5 and STAT3 phosphorylation.隐丹参酮通过靶向 STAT5 和 STAT3 磷酸化抑制慢性髓性白血病的关键致癌增殖和耐药途径。
Sci China Life Sci. 2018 Sep;61(9):999-1009. doi: 10.1007/s11427-018-9324-y. Epub 2018 Jul 20.
7
Cryptotanshinone prevents muscle wasting in CT26-induced cancer cachexia through inhibiting STAT3 signaling pathway.隐丹参酮通过抑制 STAT3 信号通路预防 CT26 诱导的癌症恶病质引起的肌肉减少症。
J Ethnopharmacol. 2020 Oct 5;260:113066. doi: 10.1016/j.jep.2020.113066. Epub 2020 Jun 4.
8
FGFR2/STAT3 Signaling Pathway Involves in the Development of MMTV-Related Spontaneous Breast Cancer in TA2 Mice.FGFR2/STAT3信号通路参与TA2小鼠中MMTV相关自发性乳腺癌的发生发展。
Front Oncol. 2020 May 5;10:652. doi: 10.3389/fonc.2020.00652. eCollection 2020.
9
STAT3/NF-κB-Regulated Lentiviral TK/GCV Suicide Gene Therapy for Cisplatin-Resistant Triple-Negative Breast Cancer.STAT3/NF-κB调控的慢病毒TK/GCV自杀基因疗法治疗顺铂耐药三阴性乳腺癌
Theranostics. 2017 Jan 15;7(3):647-663. doi: 10.7150/thno.16827. eCollection 2017.
10
LYW-6, a novel cryptotanshinone derived STAT3 targeting inhibitor, suppresses colorectal cancer growth and metastasis.LYW-6，一种新型隐丹参酮衍生的靶向 STAT3 的抑制剂，抑制结直肠癌的生长和转移。
Pharmacol Res. 2020 Mar;153:104661. doi: 10.1016/j.phrs.2020.104661. Epub 2020 Jan 23.
引用本文的文献
1
Synergistic effect of cryptotanshinone and temozolomide treatment against human glioblastoma cells.隐丹参酮与替莫唑胺联合治疗对人胶质母细胞瘤细胞的协同作用。
Sci Rep. 2023 Dec 9;13(1):21835. doi: 10.1038/s41598-023-48777-z.
2
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.用小分子化合物靶向三阴性乳腺癌中的调控细胞死亡（RCD）：从分子机制到靶向治疗的再思考视角。
J Hematol Oncol. 2022 Apr 12;15(1):44. doi: 10.1186/s13045-022-01260-0.
Zotero 插件